The original Hollings Cancer Center (HCC) Building, home to outpatient cancer services and research, was completed in 1993. Just over a decade later due to the pressing need to expand the footprint for clinical and research activities, MUSC secured $98M to add a seven-story tower and significantly renovate the original HCC Building. These projects were completed in 2007. During the initial Cancer Center Support Grant (CCSG) project period (2009-present), the HCC leadership has continued to ensure that the available facilities match the HCC's strategic plans to grow its laboratory, clinical, and cancer control-based research programs. The leadership has worked closely with the MUSC administration and architectural and engineering teams to design additional state-of-the-art facilities and space. This has led to the construction of the Drug Discovery Building (DDB) and Bioengineering Building (BEB) in late 2011, a $120M investment. The HCC has assignment of approximately three and a half floors within these two new buildings. As shown in Table 1, the total HCC-controlled space has increased to 270,174 gross ft[2], a 33% increase since the initial CCSG submission.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA138313-06
Application #
8695842
Study Section
Subcommittee G - Education (NCI)
Project Start
2009-04-01
Project End
2019-03-31
Budget Start
2014-06-20
Budget End
2015-03-31
Support Year
6
Fiscal Year
2014
Total Cost
$66,507
Indirect Cost
$22,087
Name
Medical University of South Carolina
Department
Type
DUNS #
183710748
City
Charleston
State
SC
Country
United States
Zip Code
29403
Daenthanasanmak, Anusara; Wu, Yongxia; Iamsawat, Supinya et al. (2018) PIM-2 protein kinase negatively regulates T cell responses in transplantation and tumor immunity. J Clin Invest 128:2787-2801
Rosenzweig, Steven A (2018) Acquired Resistance to Drugs Targeting Tyrosine Kinases. Adv Cancer Res 138:71-98
Min, Kyung-Won; Zealy, Richard W; Davila, Sylvia et al. (2018) Profiling of m6A RNA modifications identified an age-associated regulation of AGO2 mRNA stability. Aging Cell 17:e12753
Alawieh, Ali; Langley, E Farris; Weber, Shannon et al. (2018) Identifying the role of complement in triggering neuroinflammation after traumatic brain injury. J Neurosci :
Metelli, Alessandra; Salem, Mohammad; Wallace, Caroline H et al. (2018) Immunoregulatory functions and the therapeutic implications of GARP-TGF-? in inflammation and cancer. J Hematol Oncol 11:24
Helke, Kristi; Angel, Peggi; Lu, Ping et al. (2018) Ceramide Synthase 6 Deficiency Enhances Inflammation in the DSS model of Colitis. Sci Rep 8:1627
DeHart, David N; Lemasters, John J; Maldonado, Eduardo N (2018) Erastin-Like Anti-Warburg Agents Prevent Mitochondrial Depolarization Induced by Free Tubulin and Decrease Lactate Formation in Cancer Cells. SLAS Discov 23:23-33
Scheffel, Matthew J; Scurti, Gina; Wyatt, Megan M et al. (2018) N-acetyl cysteine protects anti-melanoma cytotoxic T cells from exhaustion induced by rapid expansion via the downmodulation of Foxo1 in an Akt-dependent manner. Cancer Immunol Immunother 67:691-702
Zunke, Friederike; Moise, Alexandra C; Belur, Nandkishore R et al. (2018) Reversible Conformational Conversion of ?-Synuclein into Toxic Assemblies by Glucosylceramide. Neuron 97:92-107.e10
Schutt, Steven D; Wu, Yongxia; Tang, Chih-Hang Anthony et al. (2018) Inhibition of the IRE-1?/XBP-1 pathway prevents chronic GVHD and preserves the GVL effect in mice. Blood Adv 2:414-427

Showing the most recent 10 out of 536 publications